This is how belly fat could increase your cancer risk

It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained. A new Michigan State University study now offers new details showing that a certain protein released from fat in the body can cause a non-cancerous cell to turn into a cancerous one. The federally funded research also found that a lower layer of abdominal fat, when compared to fat just under the skin, is the more likely culprit, releasing even more of this protein and encouraging tumor growth.

"While there have been several advances in treating cancer and improving the quality of life of patients, the number of new cases continues to surge," said Jamie Bernard, lead author and an assistant professor in pharmacology and toxicology.

"It's important to understand the cause so we can do a better job at reducing the number of cancer cases using dietary modifications or therapeutic interventions."

It's estimated that more than one-third of the population is obese. Obesity has been linked to several types of cancers including breast, colon, prostate, uterine and kidney, but Bernard indicated that just being overweight isn't necessarily the best way to determine risk.

"Our study suggests that body mass index, or BMI, may not be the best indicator," Bernard said. "It's abdominal obesity, and even more specifically, levels of a protein called fibroblast growth factor-2 that may be a better indicator of the risk of cells becoming cancerous."

There are two layers of belly fat. The top layer, known as subcutaneous fat, lies right under the skin. The layer under that, called visceral fat, is the one she found to be more harmful.

Bernard and her co-author Debrup Chakraborty, a postdoctoral student in her lab, studied mice that were fed a high-fat diet and discovered that this higher-risk layer of fat produced larger amounts of the fibroblast growth factor-2, or FGF2, protein when compared to the subcutaneous fat. They found that FGF2 stimulated certain cells that were already vulnerable to the protein and caused them to grow into tumors.

She also collected visceral fat tissue from women undergoing hysterectomies and found that when the fat secretions had more of the FGF2 protein, more of the cells formed cancerous tumors when transferred into mice.

"This would indicate that fat from both mice and humans can make a non-tumorigenic cell malignantly transform into a tumorigenic cell," Bernard said.

She added that there are several other factors released from fat, including the hormone estrogen, that could influence cancer risk, but many of those studies have only been able to show an association and not a direct cause of cancer. She also said genetics plays a role.

"There's always an element of chance in whether a person will get cancer or not," Bernard said. "But by making smarter choices when it comes to diet and exercise and avoiding harmful habits like smoking, people can always help skew the odds in their favor."

Bernard indicated that she is already looking at identifying new anti-cancer compounds in her research that could stop the effects of FGF2.

Chakraborty D, Benham V, Bullard B, Kearney T, Hsia HC, Gibbon D, Demireva EY, Lunt SY, Bernard JJ.
Fibroblast growth factor receptor is a mechanistic link between visceral adiposity and cancer.
Oncogene. 2017 Aug 7. doi: 10.1038/onc.2017.278.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]